

A Meeting of the Nutrition Society, hosted by the Irish Section, was held at the O'Reilly Hall, University College Dublin, Dublin, Republic of Ireland on 18–20 June 2008

Symposium on 'The challenge of translating nutrition research into public health nutrition'

Session 3: Joint Nutrition Society and Irish Nutrition and Dietetic Institute Symposium on 'Nutrition and autoimmune disease' PUFA, inflammatory processes and rheumatoid arthritis

Philip C. Calder

Institute of Human Nutrition, School of Medicine, University of Southampton, IDS Building, MP887, Southampton General Hospital, Tremona Road, Southampton SO16 6YD, UK

Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease manifested by swollen and painful joints, bone erosion and functional impairment. The joint lesions are characterised by infiltration of T lymphocytes, macrophages and B lymphocytes into the synovium and by synovial inflammation involving eicosanoids, cytokines and matrix metalloproteinases. In relation to inflammatory processes, the main fatty acids of interest are the *n*-6 PUFA arachidonic acid, which is the precursor of inflammatory eicosanoids such as PGE₂ and leukotriene B₄, and the *n*-3 PUFA EPA and DHA, which are found in oily fish and fish oils. Eicosanoids derived from the *n*-6 PUFA arachidonic acid play a role in RA, and the efficacy of non-steroidal anti-inflammatory drugs in RA indicates the importance of pro-inflammatory cyclooxygenase pathway products of arachidonic acid in the pathophysiology of the disease. EPA and DHA inhibit arachidonic acid metabolism to inflammatory eicosanoids. EPA also gives rise to eicosanoid mediators that are less inflammatory than those produced from arachidonic acid and both EPA and DHA give rise to resolvins that are anti-inflammatory and inflammation resolving. In addition to modifying the lipid mediator profile, *n*-3 PUFA exert effects on other aspects of immunity relevant to RA such as antigen presentation, T-cell reactivity and inflammatory cytokine production. Fish oil has been shown to slow the development of arthritis in an animal model and to reduce disease severity. Randomised clinical trials have demonstrated a range of clinical benefits in patients with RA that include reducing pain, duration of morning stiffness and use of non-steroidal anti-inflammatory drugs.

Cytokine: Eicosanoid: Fatty acid: Fish oil: Inflammation

Immune system overview

The immune system is responsible for the host's response to the presence of bacteria, viruses, fungi and parasites; it is also involved in protection against growth of certain tumours and in the response to injury and trauma. The immune system acts to distinguish between 'self' and 'non-self', permitting tolerance to self antigens and to non-threatening environmental agents such as food proteins and

commensal gut bacteria. The system has two functional divisions: the innate (or natural) immune system and the acquired (also termed specific or adaptive) immune system. Both components involve various blood-borne factors and cells. Immune cells originate in bone marrow and are found circulating in the bloodstream, organised into lymphoid organs such as the thymus, spleen, lymph nodes and gut-associated lymphoid tissue or dispersed in other locations. The immune response is typified by cellular

interactions and by the movement of cells to sites of infection or other immune activity. The four key functional activities of the immune response are:

- to act as an exclusion barrier;
- to distinguish self from non-self;
- to develop tolerance to, or to eliminate the source of, non-self antigens;
- to retain memory of immunological encounters.

In order to allow effective functioning of the immune system many different cell types, each specialised in a limited range of functions, are involved. These cells work in a coordinated integrated manner in order to assure a successful immune response.

Loss of tolerance can lead to disease and to adverse patient outcome. For example, autoimmune diseases result from loss of tolerance to self antigens, allergic diseases result from loss of tolerance to normally benign environmental or food components and inflammatory bowel diseases result from loss of tolerance to commensal gut bacteria. The loss of tolerance leads to an immunological response that is damaging to the host.

Rheumatoid arthritis

Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease that affects about 1% of the adult population and is more common in women than in men⁽¹⁾. RA is characterised by symmetric polyarthritis⁽¹⁾. Joint inflammation is manifested by swelling, pain, functional impairment, morning stiffness, osteoporosis and muscle wasting. Erosion of bone occurs commonly in the joints of the hands and feet. The joint lesions are characterised by infiltration of activated T lymphocytes, macrophages and antibody-secreting B lymphocytes into the synovium (the tissue lining the joints) and by proliferation of fibroblast-like synovial cells called synoviocytes^(1,2). These cells and new blood vessels form a tissue termed pannus that leads to progressive destruction of cartilage and bone, which is most likely to be a result of cytokine- and eicosanoid-mediated induction of destructive enzymes such as matrix metalloproteinases. RA is also characterised by signs of systemic inflammation, such as elevated plasma concentrations of some cytokines (e.g. IL-6), acute-phase proteins and rheumatoid factors.

Genetic studies have linked susceptibility to, and severity of, RA to genes in the MHC II locus; in human subjects these genes encode the human leucocyte antigen (HLA) II proteins involved in antigen presentation. RA is associated with specific alleles of the HLA-DRB1 gene, although other HLA-DR alleles may also play a role⁽³⁾. As the function of HLA-DR is antigen presentation to T lymphocytes, the genetic association indicates a role for T-cells in RA⁽⁴⁾. In total the HLA region contributes 30–50% of the genetic component of RA. The second largest genetic risk for RA lies with a variant in the protein tyrosine phosphatase non-receptor 22 gene, which encodes an intracellular protein tyrosine phosphatase⁽³⁾. The variant may act to reduce the ability to down regulate activated T-cells. Recently, novel risk loci have been described⁽³⁾.

Synovial fluid from patients with RA contains high levels of pro-inflammatory cytokines including TNF α , IL-1 β , IL-6, IL-8 and granulocyte-macrophage colony-stimulating factor⁽⁵⁾. Synovial cells cultured *ex vivo* spontaneously produce TNF α , IL-1 β , IL-6, IL-8 and granulocyte-macrophage colony-stimulating factor for extended periods of time⁽⁵⁾. Synovial fluid from patients with RA also contains high levels of anti-inflammatory cytokines such as transforming growth factor β , IL-10, IL-1 receptor antagonist and soluble TNF receptors⁽⁵⁾. Thus, the inflamed synovial joint contains excessive amounts of both pro- and anti-inflammatory cytokines, but given the ongoing state of inflammation there must be an imbalance in favour of the former.

Arachidonic acid, eicosanoids and the link with inflammation

Eicosanoids are key mediators and regulators of inflammation^(6,7) and are generated from C₂₀ PUFA. As inflammatory cells typically contain a high proportion of the *n*-6 PUFA arachidonic acid (20:4*n*-6) and low proportions of other C₂₀ PUFA, arachidonic acid is usually the major substrate for eicosanoid synthesis. Eicosanoids, which include PG, thromboxanes, leukotrienes (LT) and other oxidised derivatives, are generated from arachidonic acid by the metabolic processes summarised in Fig. 1. They are involved in modulating the intensity and duration of inflammatory responses^(6,7), have cell- and stimulus-specific sources and frequently have opposing effects. Expression of both isoforms of cyclooxygenase is increased in the synovium of patients with RA^(5,8) and in joint tissues in rat models of arthritis⁽⁸⁾. PGE₂, LTB₄ and 5-hydroxyeicosatetraenoic acid are found in the synovial fluid of patients with active RA⁽⁹⁾. Infiltrating leucocytes such as neutrophils, monocytes and synoviocytes are important sources of eicosanoids in RA⁽⁹⁾. PGE₂ has a number of pro-inflammatory effects, including increasing vascular permeability, vasodilation, blood flow and local pyrexia and potentiation of pain caused by other agents. It also promotes the production of some matrix metalloproteinases and stimulates bone resorption. The efficacy of non-steroidal anti-inflammatory drugs (NSAID), which act to inhibit cyclooxygenase activity, in RA indicates the importance of this pathway in the pathophysiology of the disease. However, although these drugs provide rapid relief of pain and stiffness by inhibiting joint inflammation, they do not influence the course of the disease. LTB₄ increases vascular permeability, enhances local blood flow, is a potent chemotactic agent for leucocytes, induces release of lysosomal enzymes and enhances release of reactive oxygen species and inflammatory cytokines such as TNF α , IL-1 β and IL-6.

Very-long-chain *n*-3 PUFA and inflammatory processes

Oily fish and fish oils contain the very-long-chain *n*-3 PUFA EPA (20:5*n*-3) and DHA (22:6*n*-3). Increased consumption of these fatty acids results in their incorporation into immune cell phospholipids^(10–13), which




Fig. 1. Outline of the pathway of eicosanoid synthesis from arachidonic acid. COX, cyclooxygenase; HETE, hydroxyeicosatetraenoic acid; HPETE, hydroperoxyeicosatetraenoic acid; LOX, lipoxygenase; LT, leukotriene; TX, thromboxane.

occurs in a dose–response fashion and is partly at the expense of arachidonic acid. The changed membrane fatty acid composition is believed to influence immune cell function and inflammatory processes⁽¹⁴⁾ (Fig. 2). There have been numerous reviews of the influence of *n*-3 PUFA on many aspects of immune function in recent years^(10–27) and the reader is referred to these articles for details beyond those provided in the following sections.

Antigen-presenting cell function

There have been several studies of the effects of *n*-3 PUFA on MHC II or HLA expression or antigen presentation via class II molecules⁽²⁸⁾. These studies have typically found that class II expression and antigen presentation via class II molecules are decreased by *n*-3 PUFA. An *in vitro* study in which spleen cells were incubated with EPA has reported decreased ability of those cells to present antigen⁽²⁹⁾; this study did not report class II expression. Incubating murine macrophages with DHA decreases expression of the class II molecules (termed Ia in mice)⁽³⁰⁾. Likewise, incubating mouse macrophages with EPA or DHA decreases interferon (IFN)- γ -induced up-regulation of class II molecules⁽³¹⁾ and incubating mouse dendritic cells with

DHA decreases endotoxin-induced class II molecule up-regulation⁽³²⁾. EPA and DHA treatment has been reported to diminish the up-regulation of HLA-DR and HLA-DP associated with IFN- γ stimulation of human monocytes⁽³³⁾. It has subsequently been demonstrated that these fatty acids decrease the ability of human monocytes to present antigen⁽³⁴⁾. Three studies, one in mice⁽³⁵⁾, one in rats⁽³⁶⁾ and one in human subjects⁽³⁷⁾ have reported effects of dietary *n*-3 PUFA on class II expression. Feeding mice fish oil, which contains EPA and DHA, results in a reduction in MHC II expression on peritoneal cells (mainly B lymphocytes and macrophages)⁽³⁵⁾. A human supplementation study with fish oil has reported decreased expression of HLA-DR, -DP and -DQ on IFN- γ -stimulated blood monocytes⁽³⁷⁾, with similar effects to those seen with *n*-3 PUFA *in vitro*⁽³³⁾. These studies did not examine antigen presentation activity. However, a study that involved feeding an EPA-rich oil to mice has shown decreased antigen (keyhole limpet (*Megathura crenulata*) haemocyanin) presentation by spleen cells to T-cell clones⁽²⁹⁾. Perhaps the most thorough study of this type to date is that in which feeding a fish oil-rich diet to rats was found to result in decreased expression of MHC II on dendritic cells⁽³⁶⁾. These cells were found to have a much reduced




Fig. 2. Mechanisms by which *n*-3 PUFA can affect inflammatory cell activity.

capacity to present antigen (keyhole limpet haemocyanin) to antigen-sensitised spleen T-cells. The reduction in antigen presentation is probably much greater than could be explained by the reduction in class II expression, suggesting that other interactions between antigen-presenting cells and T lymphocytes are affected by dietary *n*-3 PUFA. It was reported that levels of the co-stimulatory molecules CD2, CD11a and CD18 are also decreased on dendritic cells from fish oil-fed rats⁽³⁶⁾.

T lymphocyte reactivity

In vitro studies have demonstrated that EPA and DHA decrease T-cell proliferation^(38–41) and the production of helper T-cell 1-type cytokines such as IL-2^(38,39,42). Feeding studies in rodents and supplementation studies in human subjects have also shown that fish oil decreases T-cell proliferation^(43–48) and production of helper T-cell 1-type cytokines such as IL-2^(42,45,47,48) and IFN- γ ^(42,48), although it is important to note that not all human studies report such an effect⁽¹¹⁾. The reason for these discrepancies in the literature is not entirely clear, but dose of *n*-3 PUFA used, technical factors and differences among subjects studied are likely to be contributing factors.

The mechanism by which long-chain *n*-3 PUFA affect T-cell reactivity was initially thought to relate to altered patterns of eicosanoid synthesis; however, through the use of eicosanoid synthesis inhibitors and pure eicosanoids *in vitro* this mechanism has been shown to be unlikely⁽⁴⁰⁾. Studies over the last few years have demonstrated that the inhibitory effects of *n*-3 PUFA in general, and of EPA in particular, relate to membrane-mediated effects that impact on the early stages of cell signalling^(49–52).

Inflammatory mediator production

Eicosanoids. Increased consumption of very-long-chain *n*-3 PUFA such as EPA and DHA, results in decreased amounts of arachidonic acid present in immune cell membranes and available for synthesis of eicosanoids^(10–13). Thus, feeding fish oil to laboratory rodents or supplementing the diet of human subjects with fish oil has been reported to result in decreased production of a range of eicosanoids including PGE₂, thromboxane B₂, LTB₄, 5-hydroxyeicosatetraenoic acid and LTE₄ by inflammatory cells^(10–13). A recent study has demonstrated the dose-response effect to dietary EPA of PGE₂ production by endotoxin-stimulated human mononuclear cells and suggests that an EPA intake of >2 g/d is required in order to be effective⁽⁵³⁾.

EPA is also able to act as a substrate for both cyclooxygenase and 5-lipoxygenase, giving rise to eicosanoids with a slightly different structure from those formed from arachidonic acid. Thus, fish oil supplementation of the human diet has been shown to result in increased production of LTB₅, LTE₅ and 5-hydroxyeicosapentaenoic acid by inflammatory cells^(10–13). The functional importance of this outcome is that the mediators formed from EPA are frequently less potent than those formed from arachidonic acid; for example, LTB₅ is less potent as a neutrophil chemotactic agent than LTB₄^(54,55).

Resolvins and related compounds: novel EPA- and DHA-derived anti-inflammatory mediators. Recent studies have identified a novel group of trihydroxyeicosapentaenoic acid mediators, termed E-series resolvins, formed from EPA by a series of reactions involving cyclooxygenase-2 (acting in the presence of aspirin) and




Fig. 3. Cellular sites of anti-inflammatory actions of long-chain *n*-3 PUFA. IFN, interferon; Th, helper T-cell; IgG, IgG. *, Sites of action of *n*-3 PUFA; ⊘, inhibits.

5-lipoxygenase. These mediators appear to exert potent anti-inflammatory actions^(56–58). In addition, DHA-derived trihydroxydocosahexanoic acid mediators termed D-series resolvins are produced by a similar series of reactions and these resolvins are also anti-inflammatory^(59,60). Metabolism of DHA via a series of steps, several involving 5-lipoxygenase, generates a dihydroxydocosatriene termed neuroprotectin D1, again a potent anti-inflammatory molecule⁽⁶¹⁾. The identification of these novel EPA- and DHA-derived mediators is an exciting new area of *n*-3 fatty acids and inflammatory mediators and the implications to a variety of conditions may be of great importance^(62,63).

Inflammatory cytokines. Cell-culture studies have demonstrated that EPA and DHA can inhibit the production of IL-1β and TNFα by monocytes⁽⁶⁴⁾ and the production of IL-6 and IL-8 by venous endothelial cells^(65,66). Fish oil feeding decreases *ex vivo* production of TNFα, IL-1β and IL-6 by rodent macrophages^(67–69). Supplementation of the diet of healthy human volunteers with fish oil decreases production of TNF or IL-1 or IL-6 by mononuclear cells in some studies^(10–13), although a number of other studies have shown little effect of *n*-3 PUFA on production of inflammatory cytokines in human subjects⁽¹¹⁾. The reason for these discrepancies in the literature is not entirely clear, but dose of *n*-3 PUFA used, technical factors and differences among subjects studied, including genetic differences^(70,71), are likely to be contributing factors.

n-3 PUFA and animal models of rheumatoid arthritis

The effects of *n*-3 PUFA from fish oil on antigen presentation, T-cell reactivity and inflammatory lipid and peptide mediator production (Fig. 3) suggest that these fatty acids might have a role both in decreasing the risk of development of RA and in decreasing severity in those patients with the disease. Indeed, dietary fish oil has been

shown to have beneficial effects in animal models of arthritis. For example, compared with vegetable oil, feeding mice fish oil delays the onset (mean 34 d *v.* 25 d) and reduces the incidence (69% *v.* 93%) and severity (mean peak severity score 6.7 *v.* 9.8) of type II collagen-induced arthritis⁽⁷²⁾. In another study both EPA and DHA were found to suppress streptococcal cell wall-induced arthritis in rats, with EPA being more effective⁽⁷³⁾.

Trials of *n*-3 PUFA in rheumatoid arthritis

Several studies have reported anti-inflammatory effects of fish oil in patients with RA, such as decreased LTB₄ production by neutrophils^(74–77) and monocytes^(76,78), decreased PGE₂ production by mononuclear cells⁽⁷⁹⁾, decreased IL-1 production by monocytes⁽⁸⁰⁾, decreased plasma IL-1β concentrations⁽⁸¹⁾, decreased serum C-reactive protein concentrations^(74,82) and normalisation of the neutrophil chemotactic response⁽⁸³⁾. A number of randomised placebo-controlled double-blind studies of fish oil in RA have been reported. The characteristics and findings of these trials are summarised in Table 1. The dose of long-chain *n*-3 PUFA used in these trials was between 1.6 and 7.1 g/d and averaged about 3.5 g/d (see Table 1). Almost all these trials have shown some benefit of fish oil (Table 1). Such benefits include reduced duration of morning stiffness, reduced number of tender or swollen joints, reduced joint pain, reduced time to fatigue, increased grip strength and decreased use of non-steroidal anti-inflammatory drugs (Table 1). A number of reviews of these trials have been published^(84–90) and each has concluded that there is benefit from fish oil. In an editorial commentary discussing the use of fish oil in RA it was concluded that ‘the findings of benefit from fish oil in rheumatoid arthritis are robust’, ‘dietary fish oil supplements in rheumatoid arthritis have treatment efficacy’ and ‘dietary fish oil supplements should now be regarded as part of the standard therapy for rheumatoid arthritis’⁽⁹¹⁾.

Table 1. Summary of the results of placebo-controlled studies using dietary long-chain *n*-3 PUFA (in the form of fish oil) in patients with rheumatoid arthritis

Reference	Dose of EPA + DHA (g/d)	Duration (weeks)	Placebo	Clinical outcomes improved with long-chain <i>n</i> -3 PUFA
Kremer <i>et al.</i> ⁽⁷⁴⁾	1.8 + 1.2	12	Paraffin oil	No. of tender joints; duration of morning stiffness
Kremer <i>et al.</i> ⁽⁷⁵⁾	2.7 + 1.8	14	Olive oil	No. of tender joints; no. of swollen joints; time to fatigue; physician's global assessment
Cleland <i>et al.</i> ⁽⁷⁶⁾	3.2 + 2.0	12	Olive oil	No. of tender joints; grip strength
van der Tempel <i>et al.</i> ⁽⁷⁷⁾	2.0 + 1.3	12	Coconut oil	No. of swollen joints; duration of morning stiffness
Kremer <i>et al.</i> ⁽⁸⁰⁾	1.7 + 1.2	24	Olive oil	No. of tender joints; no. of swollen joints; grip strength; physician's global assessment
Kremer <i>et al.</i> ⁽⁸⁰⁾	3.5 + 2.4	24	Olive oil	No. of tender joints; no. of swollen joints; grip strength; physician's global assessment; duration of morning stiffness
Tullekan <i>et al.</i> ⁽⁷⁸⁾	2.0 + 1.3	12	Coconut oil	No. of swollen joints; joint pain
Skoldstam <i>et al.</i> ⁽⁹⁵⁾	1.8 + 1.2	24	Mixed oils	No. and severity of tender joints; physician's global assessment; use of NSAID
Esperson <i>et al.</i> ⁽⁸¹⁾	2.0 + 1.2	12	Mixed oils	No. and severity of tender joints
Nielsen <i>et al.</i> ⁽⁹⁶⁾	2.0 + 1.2	12	Vegetable oil	No. of tender joints; duration of morning stiffness
Kjeldsen-Kragh <i>et al.</i> ⁽⁹⁷⁾	3.8 + 2.0	16	Maize oil	No. and severity of tender joints; duration of morning stiffness
Lau <i>et al.</i> ⁽⁹⁸⁾	1.7 + 1.1	52	Air	Use of NSAID
Geusens <i>et al.</i> ⁽⁹⁹⁾	1.7 + 0.4	52	Olive oil	Physician's pain assessment; patient's global assessment; use of NSAID and/or disease modifying anti-rheumatic drugs
Kremer <i>et al.</i> ⁽¹⁰⁰⁾	4.6 + 2.5	26–30	Maize oil	No. of tender joints; duration of morning stiffness; physician's assessment of pain; physician's global assessment; patient's global assessment
Volker <i>et al.</i> ⁽¹⁰¹⁾	Total 40 mg/kg (approx 2.2–3.0)	15	Mixed oils	No. of swollen joints; duration of morning stiffness; patient's assessment of pain; patient's global assessment; physician's global assessment; health assessment by questionnaire
Adam <i>et al.</i> ⁽¹⁰²⁾	Approx 2.4 + 1.8	12	Maize oil	No. of swollen joints; no. of tender joints; patient's global assessment; physician's global assessment; patient's assessment of pain
Remans <i>et al.</i> ⁽¹⁰³⁾	1.4 + 0.2 (+ 0.5 γ -linolenic acid) in a liquid supplement	16	Liquid supplement without added PUFA	None
Berbert <i>et al.</i> ⁽¹⁰⁴⁾	Total 3.0		Soyabean oil	Duration of morning stiffness; joint pain; time to onset of fatigue; Ritchie's articular index*; grip strength, patient's global assessment
Sundrarjun <i>et al.</i> ⁽⁸²⁾	1.9 + 1.5	24	Not stated	None
Galarraga <i>et al.</i> ⁽¹⁰⁵⁾	1.5 + 0.7	36	Air	Use of NSAID; patient's assessment of pain

Approx, approximately; NSAID, non-steroidal anti-inflammatory drugs.

*Based on the summation of a number of quantitative evaluations of the pain experienced by the patient when the joints were subjected to pressures when exerted over the articular margin or in some instances on movement of the joint⁽¹⁰⁶⁾.

A meta-analysis that included data from nine trials published between 1985 and 1992 inclusive and from one unpublished trial has concluded that 'dietary fish oil supplementation for three months significantly reduced tender joint count (mean difference -2.9 ; $P = 0.001$) and morning stiffness (mean difference -25.9 min; $P = 0.01$)'⁽⁹²⁾. A more recent meta-analysis of data from trials published between 1985 and 2002 included one study of flaxseed oil,

one study that did not use a control for fish oil and one study in which transdermal administration of *n*-3 PUFA by ultrasound, rather than the oral route, was used⁽⁹³⁾. This meta-analysis has concluded that fish oil supplementation has no effect on 'patient report of pain, swollen joint count, disease activity or patient's global assessment'. However, this conclusion may be flawed, because of the inappropriate manner in which studies were combined and because of

Table 2. Summary of the findings of the meta-analysis of Goldberg & Katz⁽⁹⁴⁾

Outcome	No. of studies	No. of patients		Significance of effect of <i>n</i> -3 PUFA: <i>P</i>
		Control	<i>n</i> -3 PUFA	
Patient-assessed pain	13	247	254	0.03
Physician-assessed pain	3	61	62	0.45
Duration of morning stiffness	8	150	156	0.003
No. of painful and/or tender joints	10	210	215	0.003
Ritchie articular index*	4	68	67	0.40
NSAID consumption	3	79	77	0.01

NSAID, non-steroidal anti-inflammatory drugs.

*Based on the summation of a number of quantitative evaluations of the pain experienced by the patient when the joints were subjected to pressures when exerted over the articular margin or in some instances on movement of the joint⁽¹⁰⁶⁾.

a poor understanding of the study designs used. For example, the meta-analysis fails to recognise that patients' ability to reduce the need for using NSAID or their ability to be withdrawn from NSAID, as was done in some designs, must indicate a reduction in pain with *n*-3 PUFA use. This meta-analysis does state that 'in a qualitative analysis of seven studies that assessed the effect of *n*-3 fatty acids on anti-inflammatory drug or corticosteroid requirement, six demonstrated reduced requirement for these drugs' and concludes that '*n*-3 fatty acids may reduce requirements for corticosteroids'⁽⁹³⁾. The effects of long-chain *n*-3 PUFA on tender joint count were not assessed by this meta-analysis, which reiterated the findings of the earlier meta-analysis that '*n*-3 fatty acids reduce tender joint counts'⁽⁹²⁾. A recent meta-analysis of *n*-3 PUFA with data from seventeen trials included one trial of RA with flaxseed oil and two trials of fish oil not in patients with RA, but which reported joint pain⁽⁹⁴⁾. Data on six outcomes were analysed and are summarised in Table 2. This meta-analysis provides further evidence of the robustness of the efficacy of *n*-3 PUFA in RA.

Several other studies have also provided information about the benefits of *n*-3 PUFA in RA. For example, in a study that has compared outcomes among patients with RA who did and did not consume fish oil supplements it was found that fish oil users are more likely to reduce use of NSAID and are more likely to be in remission⁽⁷⁹⁾.

Overall conclusions

Eicosanoids derived from the *n*-6 PUFA arachidonic acid play a role in RA, and the efficacy of NSAID in RA indicates the importance of pro-inflammatory cyclooxygenase pathway products in the pathophysiology of the disease. At sufficiently high intakes long-chain *n*-3 PUFA decrease the production of inflammatory eicosanoids from arachidonic acid and promote the production of less-inflammatory eicosanoids from EPA and of anti-inflammatory resolvins and similar mediators from EPA and DHA. Long-chain *n*-3 PUFA have other anti-inflammatory actions including decreasing antigen presentation via MHC II, decreasing T-cell reactivity and helper T-cell 1-type cytokine production and decreasing inflammatory cytokine production by monocytes and macrophages. Work with animal models of RA has demonstrated the efficacy of fish oil. There have been a number of clinical trials of fish oil in patients with

RA. Most of these trials have reported clinical improvements (e.g. improved patient assessed pain, decreased morning stiffness, fewer painful or tender joints, decreased use of NSAID), and when the trials have been pooled in meta-analyses significant clinical benefit has emerged.

Acknowledgements

The author is a consultant to Vifor Pharma, Villars-sur-Glane, Switzerland and Danone Research Centre for Specialised Nutrition, Wageningen, The Netherlands.

References

1. Firestein GS (2003) Evolving concepts of rheumatoid arthritis. *Nature* **423**, 356–361.
2. Sweeney SE & Firestein GS (2004) Rheumatoid arthritis: regulation of synovial inflammation. *Int J Biochem Cell Biol* **36**, 372–378.
3. Bowes J & Barton A (2008) Recent advances in the genetics of RA susceptibility. *Rheumatology* **47**, 399–402.
4. Panayi GS (1999) Targetting of cells involved in the pathogenesis of rheumatoid arthritis. *Rheumatology* **38**, Suppl. 2, 8–10.
5. Feldmann M & Maini RN (1999) The role of cytokines in the pathogenesis of rheumatoid arthritis. *Rheumatology* **38**, Suppl. 2, 3–7.
6. Lewis RA, Austen KF & Soberman RJ (1990) Leukotrienes and other products of the 5-lipoxygenase pathway: biochemistry and relation to pathobiology in human diseases. *New Engl J Med* **323**, 645–655.
7. Tilley SL, Coffman TM & Koller BH (2001) Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. *J Clin Invest* **108**, 15–23.
8. Sano H, Hla T, Maier JAM, Crofford LJ, Case JP, Maciag T & Wilder RL (1992) In vivo cyclooxygenase expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis. *J Clin Invest* **89**, 97–108.
9. Sperling RI (1995) Eicosanoids in rheumatoid arthritis. *Rheum Dis Clin North Am* **21**, 741–758.
10. Calder PC (1998) *n*-3 Fatty acids and mononuclear phagocyte function. In *Medicinal Fatty Acids in Inflammation*, pp. 1–27 [JM Kremer, editor]. Basel, Switzerland: Birkhauser.
11. Calder PC (2001) *n*-3 Polyunsaturated fatty acids, inflammation and immunity: pouring oil on troubled waters or another fishy tale? *Nutr Res* **21**, 309–341.

12. Calder PC (2006) N-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. *Am J Clin Nutr* **83**, 1505S–1519S.
13. Calder PC (2007) Immunomodulation by omega-3 fatty acids. *Prostaglandins Leukot Essent Fatty Acids* **77**, 327–335.
14. Calder PC (2006) Polyunsaturated fatty acids and inflammation. *Prostaglandins Leukot Essent Fatty Acids* **75**, 197–202.
15. Calder PC (1996) Immunomodulatory and anti-inflammatory effects of omega-3 polyunsaturated fatty acids. *Proc Nutr Soc* **55**, 737–774.
16. Calder PC (1997) N-3 polyunsaturated fatty acids and cytokine production in health and disease. *Ann Nutr Metab* **41**, 203–234.
17. Miles EA & Calder PC (1998) Modulation of immune function by dietary fatty acids. *Proc Nutr Soc* **57**, 277–292.
18. Calder PC (1998) Dietary fatty acids and lymphocyte functions. *Proc Nutr Soc* **57**, 487–502.
19. Calder PC (2001) Polyunsaturated fatty acids, inflammation and immunity. *Lipids* **36**, 1007–1024.
20. Calder PC, Yaqoob P, Thies F, Wallace FA & Miles EA (2002) Fatty acids and lymphocyte functions. *Br J Nutr* **87**, S31–S48.
21. Calder PC (2003) N-3 polyunsaturated fatty acids and inflammation: from molecular biology to the clinic. *Lipids* **38**, 342–352.
22. Sijben JWC & Calder PC (2007) Differential immunomodulation with long-chain n-3 PUFA in health and disease. *Proc Nutr Soc* **66**, 237–259.
23. Yaqoob P & Calder PC (2007) Fatty acids and immune function: new insights into mechanisms. *Br J Nutr* **98**, S41–S45.
24. Yaqoob P (2003) Fatty acids as gatekeepers of immune cell regulation. *Trends Immunol* **24**, 639–645.
25. Kelley DS (2001) Modulation of human immune and inflammatory responses by dietary fatty acids. *Nutrition* **17**, 669–673.
26. Fritsche K (2006) Fatty acids as modulators of the immune response. *Annu Rev Nutr* **26**, 45–73.
27. Switzer KC, McMurray DN, Chapkin RS (2004) Effects of dietary n-3 polyunsaturated fatty acids on T-cell membrane composition and function. *Lipids* **39**, 1163–1170.
28. Calder PC (2007) Polyunsaturated fatty acids alter the rules of engagement. *Future Lipidol* **2**, 27–30.
29. Fujikawa M, Yamashita N, Yamazaki K, Sugiyama E, Suzuki H & Hamazaki T (1992) Eicosapentaenoic acid inhibits antigen-presenting cell function of murine splenocytes. *Immunology* **75**, 330–335.
30. Khair-el-Din TA, Sicher SC, Vazquez MA & Lu CY (1996) Inhibition of macrophage nitric-oxide production and Ia-expression by docosahexaenoic acid, a constituent of fetal and neonatal serum. *Am J Reprod Immunol* **36**, 1–10.
31. Khair-el-Din TA, Sicher SC, Vazquez MA, Wright WJ & Lu CY (1995) Docosahexaenoic acid, a major constituent of fetal serum and fish oil diets, inhibits IFN gamma-induced Ia-expression by murine macrophages in vitro. *J Immunol* **154**, 1296–1306.
32. Weatherill AR, Lee JY, Zhao L, Lemay DG, Youn HS & Hwang DH (2005) Saturated and polyunsaturated fatty acids reciprocally modulate dendritic cell functions mediated through TLR4. *J Immunol* **174**, 5390–5397.
33. Hughes DA, Southon S & Pinder AC (1996) (n-3) Polyunsaturated fatty acids modulate the expression of functionally associated molecules on human monocytes in vitro. *J Nutr* **126**, 603–610.
34. Hughes DA & Pinder AC (1997) N-3 polyunsaturated fatty acids modulate the expression of functionally associated molecules on human monocytes and inhibit antigen-presentation in vitro. *Clin Exp Immunol* **110**, 516–523.
35. Huang SC, Misfeldt ML & Fritsche KL (1992) Dietary fat influences Ia antigen expression and immune cell populations in the murine peritoneum and spleen. *J Nutr* **122**, 1219–1231.
36. Sanderson P, MacPherson GG, Jenkins CH & Calder PC (1997) Dietary fish oil diminishes the antigen presentation activity of rat dendritic cells. *J Leukoc Biol* **62**, 771–777.
37. Hughes DA, Pinder AC, Piper Z, Johnson IT & Lund EK (1996) Fish oil supplementation inhibits the expression of major histocompatibility complex class II molecules and adhesion molecules on human monocytes. *Am J Clin Nutr* **63**, 267–272.
38. Calder PC & Newsholme EA (1992) Unsaturated fatty acids suppress interleukin-2 production and transferrin receptor expression by concanavalin A-stimulated rat lymphocytes. *Mediators Inflamm* **1**, 107–115.
39. Calder PC & Newsholme EA (1992) Polyunsaturated fatty acids suppress human peripheral blood lymphocyte proliferation and interleukin-2 production. *Clin Sci (Lond)* **82**, 695–700.
40. Calder PC, Bevan SJ & Newsholme EA (1992) The inhibition of T-lymphocyte proliferation by fatty acids is via an eicosanoid-independent mechanism. *Immunology* **75**, 108–115.
41. Calder PC, Yaqoob P, Harvey DJ, Watts A & Newsholme EA (1994) The incorporation of fatty acids by lymphocytes and the effect on fatty acid composition and membrane fluidity. *Biochem J* **300**, 509–518.
42. Wallace FA, Miles EA, Evans C, Stock TE, Yaqoob P & Calder PC (2001) Dietary fatty acids influence the production of Th1- but not Th2-type cytokines. *J Leukoc Biol* **69**, 449–457.
43. Yaqoob P, Newsholme EA & Calder PC (1994) The effect of dietary lipid manipulation on rat lymphocyte subsets and proliferation. *Immunology* **82**, 603–610.
44. Yaqoob P & Calder PC (1995) The effects of dietary lipid manipulation on the production of murine T-cell-derived cytokines. *Cytokine* **7**, 548–553.
45. Jolly CA, Jiang YH, Chapkin RS & McMurray DN (1997) Dietary (n-3) polyunsaturated fatty acids suppress murine lymphoproliferation, interleukin-2 secretion, and the formation of diacylglycerol and ceramide. *J Nutr* **127**, 37–43.
46. Peterson LD, Jeffery NM, Thies F, Sanderson P, Newsholme EA & Calder PC (1998) Eicosapentaenoic and docosahexaenoic acids alter rat spleen leukocyte fatty acid composition and prostaglandin E₂ production but have different effects on lymphocyte functions and cell-mediated immunity. *Lipids* **33**, 171–180.
47. Meydani SN, Endres S, Woods MM, Goldin BR, Soo C, Morrill-Labrode A, Dinarello CA & Gorbach SL (1991) Oral (n-3) fatty acid supplementation suppresses cytokine production and lymphocyte proliferation: comparison between young and older women. *J Nutr* **121**, 547–555.
48. Trebble TM, Wootton SA, Miles EA, Mullee M, Arden NK, Ballinger AB, Stroud MA & Calder PC (2003) Prostaglandin E₂ production and T-cell function after fish-oil supplementation: response to antioxidant co-supplementation. *Am J Clin Nutr* **78**, 376–382.
49. Sanderson P & Calder PC (1998) Dietary fish oil appears to inhibit the activation of phospholipase C- γ in lymphocytes. *Biochim Biophys Acta* **1392**, 300–308.
50. Stulnig TM, Huber J, Leitinger N, Imre EM, Angelisova P, Nowotny P & Waldhausl W (2001) Polyunsaturated

- eicosapentaenoic acid displaces proteins from membrane rafts by altering raft lipid composition. *J Biol Chem* **276**, 37335–37340.
51. Zeyda M, Staffler G, Horejsi V, Waldhausl W & Stulnig TM (2002) LAT displacement from lipid rafts as a molecular mechanism for the inhibition of T cell signaling by polyunsaturated fatty acids. *J Biol Chem* **277**, 28418–28423.
 52. Zeyda M, Szekeres AB, Säemann MD, Geyeregger R, Stockinger H, Zlabinger GJ, Waldhäusl W & Stulnig TM (2003) Suppression of T cell signaling by polyunsaturated fatty acids: selectivity in inhibition of mitogen-activated protein kinase and nuclear factor activation. *J Immunol* **170**, 6033–6039.
 53. Rees D, Miles EA, Banerjee T, Wells SJ, Roynette CE, Wahle KWJW & Calder PC (2006) Dose-related effects of eicosapentaenoic acid on innate immune function in healthy humans: a comparison of young and older men. *Am J Clin Nutr* **83**, 331–342.
 54. Goldman DW, Pickett WC & Goetzl EJ (1983) Human neutrophil chemotactic and degranulating activities of leukotriene B₅ (LTB₅) derived from eicosapentaenoic acid. *Biochem Biophys Res Commun* **117**, 282–288.
 55. Lee TH, Mencia-Huerta JM, Shih C, Corey EJ, Lewis RA & Austen KF (1984) Characterization and biologic properties of 5,12-dihydroxy derivatives of eicosapentaenoic acid, including leukotriene-B₅ and the double lipooxygenase product. *J Biol Chem* **259**, 2383–2389.
 56. Serhan CN, Clish CB, Brannon J, Colgan SP, Gronert K & Chiang N (2000) Anti-inflammatory lipid signals generated from dietary n-3 fatty acids via cyclooxygenase-2 and transcellular processing: a novel mechanism for NSAID and n-3 PUFA therapeutic actions. *J Physiol Pharmacol* **4**, 643–654.
 57. Serhan CN, Clish CB, Brannon J, Colgan SP, Chiang N & Gronert K (2000) Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. *J Exp Med* **192**, 1197–1204.
 58. Serhan CN, Hong S, Gronert K, Colgan SP, Devchand PR, Mirick G & Moussignac R-L (2002) Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. *J Exp Med* **196**, 1025–1037.
 59. Hong S, Gronert K, Devchand P, Moussignac R-L & Serhan CN (2003) Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood and glial cells: autocooids in anti-inflammation. *J Biol Chem* **278**, 14677–14687.
 60. Marcheselli VL, Hong S, Lukiw WJ & Hua Tian X (2003) Novel docosanoids inhibit brain ischemia reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. *J Biol Chem* **278**, 43807–43817.
 61. Mukherjee PK, Marcheselli VL, Serhan CN & Bazan NG (2004) Neuroprotectin D1: A docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. *Proc Natl Acad Sci U S A* **101**, 8491–8496.
 62. Serhan CN, Arita M, Hong S & Gotlinger K (2004) Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their endogenous aspirin-triggered epimers. *Lipids* **39**, 1125–1132.
 63. Serhan CN (2005) Novel eicosanoid and docosanoid mediators: resolvins, docosatrienes, and neuroprotectins. *Curr Opin Clin Nutr Metab Care* **8**, 115–121.
 64. Babcock TA, Novak T, Ong E, Jho DH, Helton WS & Espat NJ (2002) Modulation of lipopolysaccharide-stimulated macrophage tumor necrosis factor- α production by -3 fatty acid is associated with differential cyclooxygenase-2 protein expression and is independent of interleukin-10. *J Surg Res* **107**, 135–139.
 65. De Caterina R, Cybulsky MI, Clinton SK, Gimbrone MA & Libby P (1994) The omega-3 fatty acid docosahexaenoate reduces cytokine-induced expression of proatherogenic and proinflammatory proteins in human endothelial cells. *Arterioscler Thromb* **14**, 1829–1836.
 66. Khalfoun B, Thibault F, Watier H, Bardos P & Lebranchu Y (1997) Docosahexaenoic and eicosapentaenoic acids inhibit in vitro human endothelial cell production of interleukin-6. *Adv Exp Biol Med* **400**, 589–597.
 67. Billiar T, Bankey P, Svingen B, Curran RD, West MA, Holman RT, Simmons RL & Cerra FB (1988) Fatty acid uptake and Kupffer cell function: fish oil alters eicosanoid and monokine production to endotoxin stimulation. *Surgery* **104**, 343–349.
 68. Renier G, Skamene E, de Sanctis J & Radzioch D (1993) Dietary n-3 polyunsaturated fatty acids prevent the development of atherosclerotic lesions in mice: modulation of macrophage secretory activities. *Arterioscler Thromb* **13**, 1515–1524.
 69. Yaqoob P & Calder PC (1995) Effects of dietary lipid manipulation upon inflammatory mediator production by murine macrophages. *Cell Immunol* **163**, 120–128.
 70. Grimble RF, Howell WM, O'Reilly G, Turner SJ, Markovic O, Hirrell S, East JM & Calder PC (2002) The ability of fish oil to suppress tumor necrosis factor- α production by peripheral blood mononuclear cells in healthy men is associated with polymorphisms in genes that influence tumor necrosis factor α production. *Am J Clin Nutr* **76**, 454–459.
 71. Shen J, Arnett DK, Peacock JM *et al.* (2007) Interleukin1beta genetic polymorphisms interact with polyunsaturated fatty acids to modulate risk of the metabolic syndrome. *J Nutr* **137**, 1846–1851.
 72. Leslie CA, Gonnerman WA, Ullman MD, Hayes KC, Franzblau C & Cathcart ES (1985) Dietary fish oil modulates macrophage fatty acids and decreases arthritis susceptibility in mice. *J Exp Med* **162**, 1336–1349.
 73. Volker DH, FitzGerald PEB & Garg ML (2000) The eicosapentaenoic to docosahexaenoic acid ratio of diets affects the pathogenesis of arthritis in Lew/SSN rats. *J Nutr* **130**, 559–565.
 74. Kremer JM, Bigauette J, Michalek AV, Timchalk MA, Lininger L, Rynes RI, Huyck C, Zieminski J & Bartholomew LE (1985) Effects of manipulation of dietary fatty acids on manifestations of rheumatoid arthritis. *Lancet* **i**, 184–187.
 75. Kremer JM, Jubiz W, Michalek A, Rynes RI, Bartholomew LE, Bigouette J, Timchalk M, Beller D & Lininger L (1987) Fish-oil supplementation in active rheumatoid arthritis. *Ann Intern Med* **106**, 497–503.
 76. Cleland LG, French JK, Betts WH, Murphy GA & Elliot MJ (1988) Clinical and biochemical effects of dietary fish oil supplements in rheumatoid arthritis. *J Rheumatol* **15**, 1471–1475.
 77. van der Tempel H, Tullean JE, Limburg PC, Muskiet FAJ & van Rijswijk MH (1990) Effects of fish oil supplementation in rheumatoid arthritis. *Ann Rheum Dis* **49**, 76–80.
 78. Tullean JE, Limburg PC, Muskiet FAJ & van Rijswijk MH (1990) Vitamin E status during dietary fish oil supplementation in rheumatoid arthritis. *Arthritis and Rheumatism* **33**, 1416–1419.
 79. Cleland LG, Caughey GE, James MJ & Proudman SM (2006) Reduction of cardiovascular risk factors with

longterm fish oil treatment in early rheumatoid arthritis. *J Rheumatol* **33**, 1973–1979.

80. Kremer JM, Lawrence DA, Jubiz W, DiGiacomo R, Rynes R, Bartholomew LE & Sherman M (1990) Dietary fish oil and olive oil supplementation in patients with rheumatoid arthritis. *Arthritis Rheumatol* **33**, 810–820.
81. Esperson GT, Grunnet N, Lervang HH, Nielsen GL, Thomsen BS, Faarvang KL, Dyerberg J & Ernst E (1992) Decreased interleukin-1 beta levels in plasma from rheumatoid arthritis patients after dietary supplementation with n-3 polyunsaturated fatty acids. *Clin Rheumatol* **11**, 393–395.
82. Sundrarjun T, Komindr S, Archararit N, Dahaln W, Puchaiwatananon O, Angtharakar S, Udomsuppayakui U & Chuncharunee S (2004) Effects of n-3 fatty acids on serum interleukin-6, tumour necrosis factor-alpha and soluble tumour necrosis factor receptor p55 in active rheumatoid arthritis. *J Int Med Res* **32**, 443–454.
83. Sperling RI, Weinblatt M, Robin JL, Ravalese J, Hoover RL, House F, Coblyn JS, Fraser PA, Spur BW & Robinson DR (1987) Effects of dietary supplementation with marine fish oil on leukocyte lipid mediator generation and function in rheumatoid arthritis. *Arthritis Rheum* **30**, 988–997.
84. James MJ & Cleland LG (1997) Dietary n-3 fatty acids and therapy for rheumatoid arthritis. *Semin Arthritis Rheum* **27**, 85–97.
85. Geusens PP (1998) n-3 Fatty acids in the treatment of rheumatoid arthritis. In *Medicinal Fatty Acids in Inflammation*, pp. 111–123 [JM Kremer, editor]. Basel, Switzerland: Birkhauser.
86. Kremer JM (2000) N-3 fatty acid supplements in rheumatoid arthritis. *Am J Clin Nutr* **71**, 349S–351S.
87. Volker D & Garg M (1996) Dietary n-3 fatty acid supplementation in rheumatoid arthritis – mechanisms, clinical outcomes, controversies, and future directions. *J Clin Biochem Nutr* **20**, 83–87.
88. Calder PC (2001) The scientific basis for fish oil supplementation in rheumatoid arthritis. In *Nutritional Supplements in Health and Disease*, pp. 175–197 [JK Ransley, JK Donnelly and NW Read, editors]. London: Springer Verlag.
89. Calder PC & Zurier RB (2001) Polyunsaturated fatty acids and rheumatoid arthritis. *Curr Opin Clin Nutr Metab Care* **4**, 115–121.
90. Cleland LG, James MJ & Proudman SM (2003) The role of fish oils in the treatment of rheumatoid arthritis. *Drugs* **63**, 845–853.
91. Cleland LG & James MJ (2000) Fish oil and rheumatoid arthritis: antiinflammatory and collateral health benefits. *J Rheumatol* **27**, 2305–2307.
92. Fortin PR, Lew RA, Liang MH, Wright EA, Beckett LA, Chalmers TC & Sperling RI (1995) Validation of a meta-analysis: The effects of fish oil in rheumatoid arthritis. *J Clin Epidemiol* **48**, 1379–1390.
93. MacLean CH, Mojica WA, Morton SC *et al.* (2004) *Effects of Omega-3 Fatty Acids on Inflammatory Bowel Disease, Rheumatoid Arthritis, Renal Disease, Systemic Lupus Erythematosus, and Osteoporosis, Evidence Report/Technical Assessment* no. 89. *AHRQ Publication* no. 04-E012-2. Rockville, MD: Agency for Healthcare Research and Quality; available at <http://www.ahrq.gov/clinic/tp/o3lipidtp.htm>
94. Goldberg RJ & Katz J (2007) A meta-analysis of the analgesic effects of omega-3 polyunsaturated fatty acid supplementation for inflammatory joint pain. *Pain* **129**, 210–233.
95. Skoldstam L, Borjesson O, Kjallman A, Seiving B & Akesson B (1992) Effect of six months of fish oil supplementation in stable rheumatoid arthritis: a double blind, controlled study. *Scand J Rheumatol* **21**, 178–185.
96. Nielsen GL, Faarvang KL, Thomsen BS, Teglbjaerg KL, Jensen LT, Hansen TM, Lervang HH, Schmidt EB, Dyerberg J & Ernst E (1992) The effects of dietary supplementation with n-3 polyunsaturated fatty acids in patients with rheumatoid arthritis: a randomized, double blind trial. *Eur J Clin Invest* **22**, 687–691.
97. Kjeldsen-Kragh J, Lund JA, Riise T, Finnanger B, Haaland K, Finstad R, Mikkelsen K & Forre O (1992) Dietary omega-3 fatty acid supplementation and naproxen treatment in patients with rheumatoid arthritis. *J Rheumatol* **19**, 1531–1536.
98. Lau CS, Morley KD & Belch JFF (1993) Effects of fish oil supplementation on non-steroidal anti-inflammatory drug requirement in patients with mild rheumatoid arthritis. *Br J Rheumatol* **32**, 982–989.
99. Geusens P, Wouters C, Nijs J, Jiang Y & Dequeker J (1994) Long-term effect of omega-3 fatty acid supplementation in active rheumatoid arthritis. *Arthritis Rheum* **37**, 824–829.
100. Kremer JM, Lawrence DA, Petrillo GF, Litts LL, Mullaly PM, Rynes RI, Stocker RP, Parhami N, Greenstein NS & Fuchs BR (1995) Effects of high-dose fish oil on rheumatoid arthritis after stopping nonsteroidal antiinflammatory drugs: clinical and immune correlates. *Arthritis Rheum* **38**, 1107–1114.
101. Volker D, Fitzgerald P, Major G & Garg M (2000) Efficacy of fish oil concentrate in the treatment of rheumatoid arthritis. *J Rheumatol* **27**, 2343–2346.
102. Adam O, Beringer C, Kless T, Lemmen C, Adam A, Wiseman M, Adam P, Klimmek R & Forth W (2003) Anti-inflammatory effects of a low arachidonic acid diet and fish oil in patients with rheumatoid arthritis. *Rheumatol Int* **23**, 27–36.
103. Remans PH, Sont JK, Wagenaar LW, Wouters-Wesseling W, Zuijderduin WM, Jongma A, Breedveld FC & van Laar JM (2004) Nutrient supplementation with polyunsaturated fatty acids and micronutrients in rheumatoid arthritis: clinical and biochemical effects. *Eur J Clin Nutr* **58**, 839–845.
104. Berbert AA, Kondo CR, Almendra CL, Matsuo T & Dichi I (2005) Supplementation of fish oil and olive oil in patients with rheumatoid arthritis. *Nutrition* **21**, 131–136.
105. Galarraga B, Ho, M, Youssef HM, Hill A, McMahon H, Hall C, Ogston S, Nuki G & Belch JFF (2008) Cod liver oil (n-3 fatty acids) as a non-steroidal anti-inflammatory drug sparing agent in rheumatoid arthritis. *Rheumatology* **47**, 665–669.
106. Ritchie DA, Boyle JA, McInnes JM, Jasani MK, Dalakos TG, Grievson P & Buchanan WW (1969) Evaluation of a simple articular index for joint tenderness in rheumatoid arthritis. *Ann Rheum Dis* **28**, 196.